18f-mfbg
Small moleculeexperimentalImaging agent
Clinical trial activity
7 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02348749)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f-mfbg
- 18f-mfbg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07176286 | Phase 2 | Nov 30, 2025 | Illumina, Inc., The University of Texas, Dallas |
| NCT06233903 | Phase 2 | Jan 31, 2025 | Illumina, Inc., Yeshiva University |
| NCT04724369 | Phase 3 | Sep 24, 2021 | Illumina, Inc., Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI) |
| NCT05069220 | Early Phase 1 (Phase 1) | Sep 1, 2021 | Chinese Academy of Medical Sciences |
| NCT04535193 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2020 | Icahn School of Medicine at Mount Sinai, Illumina, Inc. |
| NCT04258592 | Phase 1 | Feb 7, 2020 | Katholieke Universiteit Leuven |
| NCT02348749 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Cornell University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Illumina, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Yeshiva University | Academic/Hospital | 1 | 0 | 1 | 2025 |
9 organizations
Page 1 / 1